Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Eric Christensen.

Thank you so much for listening today. Go check out RealLife Pharmacology.com. Get your free study guide on the top 200 drugs.

Simply in email, we'll get you access to that free resource. And obviously, we'll get you updates when we've got new podcasts available as well as other new

content.

So go check that out at real-life pharmacology.com.

All right, the drug of the day today is ropineral or brand name Requip.

This drug is classified as a dopamine agonist.

With that said, what dopamine receptors, from a mechanism of action standpoint, does

ripinerol bind? It primarily binds D3 receptors, but it also does have some binding to D2 receptors.

So if you remember mechanistically and from a drug class perspective, antipsychotics block dopamine 2 receptors.

And a drug like repineral actually activates or agonizes.

It stimulates the D2 receptor.

So these two drugs can really kind of cause opposing type effects.

So that's definitely an important thing to remember.

And if you can remember some of the adverse effects of antipsychotics, you can expect,

or what the antipsychotics treat, you can expectropineral to have some of the opposite type activity. And we'll get into that when I talk about

adverse effects, especially. All right, let's talk about indications. So first and foremost, this

drug was, I believe, initially created to manage Parkinson's symptoms.

Having that dopamine action, remember Parkinson's, it's a lack of dopamine action in the brain.

So it makes sense that ropeinerol could potentially be helpful for Parkinson's.

Now, with that, Carbidopal Leavidopa is really the gold standard for treatment of Parkinson's. Now, with that, Carbidopaliva is really the gold standard for treatment of Parkinson's,

so in my practice, I really don't see it used very often for Parkinson's disease. The other primary

...